Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer

Table 2

Trials using Anti-EGFR mABs as monotherapy for chemoresistant mCRC selected by KRAS status.

Trial (author)	Phase	KRAS	Protocol	Number enrolled	Results		HR (95% CI)	𝑃 value
					PFS	OS
— (Amado et al.) [14]	III	WT	Panitumumab; BSC	124; 119	12.3 wks.; 7.3 wks.	8.1 mos.; 7.6 mos.	PFS: 0.45 (0.34–0.59); OS: 0.99 (0.75–1.29)	<0.001; NR
		MUT	Panitumumab; BSC	84; 100	7.4 wks.; 7.3 wks.	4.9 mos.; 4.4 mos.	PFS: 0.99 (0.73–1.36); OS: 1.02 (0.75–1.39)	NR; NR

BSC: best supportive care, WT: wild type, MUT: mutated, and NR: not reported.